/

MCUJF

Medicure Inc.Closed

2.76−0.04 −1.43%USD

OTC Markets OTCPK · as of Oct 14, 15:56 ET · 15m delay

Open

2.83

Prev close

2.80

Day range

2.752.99

52-week range

0.67003.45

Volume

15.30K1.82×

Mkt cap

30.93M

P/E ttm

—

Fwd P/E

4.25

EPS ttm

-0.5100

Div yield

0.00%

Earnings

—

From 52w high

−20.00%

Price Chart

Yahoo Finance · delayed

MCUJFOct 14, 2026O 2.83H 2.99L 2.75C 2.76−0.04 (−1.43%)Vol 15.30K

SMA 501.62
SMA 2001.01

1Y change +268.00% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

MCUJF Medicure Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +33.33%
1 month: +54.19%
3 months: +311.94%
6 months: +187.50%
Year to date: +245.00%
1 year: +253.85%

Valuation & ownership

Market cap: 30.93M
Enterprise value: 27.67M
P/E (ttm): —
Forward P/E: 4.25
PEG ratio: —
Price / book: 3.54
Price / sales (ttm): 0.96
EV / EBITDA: -4.93
EPS (ttm): -0.5100
EPS (forward): 0.6500
Beta (5y monthly): 1.15
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 10.44M
Float: 5.22M
Short % of float: —
Short ratio (days): 1.85
Held by insiders: 27.30%
Held by institutions: 23.10%
Avg volume (3m): 8.39K
50-day average: 1.59
200-day average: 1.01
52-week change: +253.85%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): overbought 88.6
vs 50-day SMA: +69.99%
vs 200-day SMA: +172.03%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 7.22%
Realised vol (20d, ann.): 103.5%
From 52-week high: −20.00%
From 52-week low: +311.94%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 32.08M
Revenue growth (yoy): +11.40%
Earnings growth (yoy): —
Gross margin: 38.00%
Operating margin: -18.22%
Profit margin: -23.23%

DES

About Medicure Inc.

Yahoo Finance profile

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order, and online pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Headquarters: Winnipeg, MB, Canada
Website: medicure.com
Officers: Dr. Albert David Friesen Ph.D. Founder, CEO, President & Chairman of the Board
Mr. James F. Kinley C.A., CPA Interim CFO & Director
Dr. Reuben Saba Ph.D. Vice President of Scientific & Medical Affairs

SEAS

Seasonality · MCUJF

2007–2026 · monthly returns

Strongest month Jan +21.55%Weakest month Mar −9.51%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	17.5	-4.3	-11.1	-6.3	6.7	-16.2	32.8	111.2	6.4	38.0			+245.0%
2025	-14.5	0.0	-13.2	30.4	31.7	15.2	3.3	-24.5	0.0	31.0	-20.4	8.1	+29.0%
2024	28.2	-12.0	-3.4	-12.9	1.4	14.7	-14.0	8.1	-3.8	-18.2	11.1	-11.4	−20.5%
2023	18.5	-10.4	-4.7	15.9	-2.1	7.5	6.0	-10.4	15.8	-0.9	7.3	-33.3	−3.7%
2022	0.0	8.2	2.5	1.2	11.0	-11.0	19.8	-19.6	-11.5	33.3	-6.5	-5.8	+11.0%
2021	34.0	-3.2	0.8	5.7	-13.1	-17.7	-1.1	-9.8	-7.2	0.0	1.3	-6.4	−22.3%
2020	-12.0	-28.3	-39.5	-25.8	-14.1	2.5	3.7	-3.6	-16.0	-13.2	6.8	49.2	−71.1%
2019	11.3	-1.4	-3.9	0.2	-13.5	-8.1	-6.2	-4.0	1.5	-24.1	42.6	-11.7	−26.6%
2018	0.5	-3.0	-9.9	-2.9	10.1	-3.6	0.0	1.1	2.2	-3.4	-11.4	-6.1	−24.9%
2017	-4.9	-7.8	7.6	-12.9	-26.8	36.0	4.1	-7.4	4.9	1.4	-13.1	3.7	−24.5%
2016	46.7	19.3	-13.3	-2.4	-5.8	18.6	-8.7	8.7	-2.6	-10.1	34.6	32.8	+156.9%
2015	-43.4	70.7	-11.2	49.3	-12.9	-2.6	18.4	0.4	20.8	-9.9	17.5	5.2	+73.7%
2014	31.8	86.2	68.5	91.2	-3.4	7.7	40.3	5.9	-31.2	6.5	-5.1	-6.4	+695.5%
2013	-18.8	30.8	-35.3	13.6	-24.0	-15.8	-18.8	15.4	6.7	100.0	-31.2	0.0	−31.2%
2012	50.0	33.3	-25.0	0.0	33.3	0.0	-25.0	33.3	0.0	-25.0	20.0	-40.7	+6.7%
2011	100.0	0.0	0.0	-50.0	100.0	50.0	33.3	0.0	-50.0	50.0	-33.3	0.0	+100.0%
2010	0.0	0.0	-50.0	0.0	100.0	-50.0	0.0	0.0	0.0	0.0	0.0	0.0	−50.0%
2009	200.0	0.0	-33.3	50.0	0.0	0.0	-33.3	0.0	50.0	0.0	0.0	-33.3	+100.0%
2008	-15.7	-88.4	-20.0	-12.5	-14.3	-33.3	-50.0	100.0	-50.0	50.0	-66.7	0.0	−99.0%
2007	-2.5	-8.4	2.8	18.8	-14.3	19.3	4.4	-15.5	-5.8	-13.3	-25.5	39.7	−16.4%

INSD

Insider Activity · MCUJF

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jun 21, 2026	Friesen (Albert David)Director of Issuer	Acquisition in the public market at price 0.87 per share.	1K	$869
Jun 21, 2026	Friesen (Albert David)Director of Issuer	Acquisition in the public market at price 0.85 per share.	200	$169
Jun 21, 2026	Friesen (Albert David)Director of Issuer	Acquisition in the public market at price 0.88 per share.	2.5K	$2.21K
Jun 18, 2026	Friesen (Albert David)Director of Issuer	Acquisition in the public market at price 0.85 per share.	16.3K	$13.82K
Jun 18, 2026	Friesen (Albert David)Director of Issuer	Acquisition in the public market at price 0.86 per share.	2K	$1.72K

MCUJF

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

MCUJF

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Medicure Inc.

Seasonality · MCUJF

Insider Activity · MCUJF

Congress Trades · MCUJF

Investors Holding MCUJF

Investors Holding MCUJF

Congress Trades · MCUJF

Seasonality · MCUJF

Insider Activity · MCUJF

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Medicure Inc.

Earnings & Dividends

News